Charles Fuchs, MD: Strategies to Increase RAS Testing

Video

What strategies can be used to increase the percentage of patients who receive recommended RAS testing?

It's really important and incumbent upon us to make sure that these data are available to all practicing oncologists. ASCO, OncLive, and other organizations are doing a good job proliferating that information, making sure that busy practitioners are aware of the data that RAS and KRAS and NRAS specifically decide for us whether a patient should get an EGFR receptor inhibitor, and that you should not be making these treatment decisions without obtaining that testing.

Unresectable Colon Cancer: Case 2

52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.

Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Jordyn Sava
November 21st 2024
Article

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

FDA Approves Cologuard Plus Stool DNA Test for Colorectal Cancer Screening

FDA Approves Cologuard Plus Stool DNA Test for Colorectal Cancer Screening

Sabrina Serani
October 4th 2024
Article

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

No Survival Advantage Seen With Ramucirumab and TAS-102 in Metastatic Colorectal Cancer

No Survival Advantage Seen With Ramucirumab and TAS-102 in Metastatic Colorectal Cancer

Caroline Seymour
September 15th 2024
Article

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone in heavily pretreated metastatic colorectal cancer.

Read More

Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback

Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback

Jordyn Sava
July 18th 2024
Article

Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.

Read More